41 related articles for article (PubMed ID: 29993225)
1. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.
Klara K; Kim J; Ross JS
J Gen Intern Med; 2018 May; 33(5):651-658. PubMed ID: 29484575
[TBL] [Abstract][Full Text] [Related]
2. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints.
Kesselheim AS; Mello MM; Studdert DM
PLoS Med; 2011 Apr; 8(4):e1000431. PubMed ID: 21483716
[TBL] [Abstract][Full Text] [Related]
3. A critical review of methods to evaluate the impact of FDA regulatory actions.
Briesacher BA; Soumerai SB; Zhang F; Toh S; Andrade SE; Wagner JL; Shoaibi A; Gurwitz JH
Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):986-94. PubMed ID: 23847020
[TBL] [Abstract][Full Text] [Related]
4. The new FDA labeling rule: impact on prescribing rheumatological medications during pregnancy.
Bermas BL; Tassinari M; Clowse M; Chakravarty E
Rheumatology (Oxford); 2018 Jul; 57(suppl_5):v2-v8. PubMed ID: 30137587
[TBL] [Abstract][Full Text] [Related]
5. The First Amendment Right to Speak About the Human Genome.
Evans BJ
Univ Pa J Const Law; 2014 Feb; 16(3):549-636. PubMed ID: 25473380
[TBL] [Abstract][Full Text] [Related]
6. Medicolegal Sidebar: Free Speech Rights Versus Off-Label Use.
Green SA; Bal BS
Clin Orthop Relat Res; 2023 Jul; 481(7):1285-1287. PubMed ID: 37229553
[No Abstract] [Full Text] [Related]
7. Off-label drug promotion now on the table: house and senate voice concerns.
Barlas S
P T; 2008 Feb; 33(2):73-5. PubMed ID: 19750002
[No Abstract] [Full Text] [Related]
8. Promotion of Drugs for Off-label Uses: The US Food and Drug Administration at a Crossroads.
Kim J; Kapczynski A
JAMA Intern Med; 2017 Feb; 177(2):157-158. PubMed ID: 27820607
[No Abstract] [Full Text] [Related]
9. FDA Regulation of Prescription Drugs.
Gassman AL; Nguyen CP; Joffe HV
N Engl J Med; 2017 Feb; 376(7):674-682. PubMed ID: 28199811
[No Abstract] [Full Text] [Related]
10. United States v. Caronia: Off-Label Drug Promotion and First Amendment Balancing.
Rabinowitz DP
Fordham Law Rev; 2018 Apr; 86(5):2595-623. PubMed ID: 29993225
[TBL] [Abstract][Full Text] [Related]
11. Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases.
Liu S; Mello MM; Kesselheim AS
J Health Polit Policy Law; 2021 Jun; 46(3):487-504. PubMed ID: 33647951
[TBL] [Abstract][Full Text] [Related]
12. Snake oil salesmen or purveyors of knowledge: off-label promotions and the commercial speech doctrine.
Bagley CE; Mitts J; Tinsley RJ
Cornell J Law Public Policy; 2013; 23(2):337-93. PubMed ID: 25330567
[TBL] [Abstract][Full Text] [Related]
13. The ban on "off-label" pharmaceutical promotion: constitutionally permissible prophylaxis against false or misleading commercial speech?
Greenwood K
Am J Law Med; 2011; 37(2-3):278-98. PubMed ID: 21847882
[TBL] [Abstract][Full Text] [Related]
14. Off-label marketing and the First Amendment.
Boumil MM
N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
[No Abstract] [Full Text] [Related]
15. Inconsistent government policies: why FDA off-label regulation cannot survive First Amendment review under Greater New Orleans.
Hall RF; Sobotka E
Food Drug Law J; 2007; 62(1):1-48. PubMed ID: 17444025
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
